Jay Sosenko
Overview
Explore the profile of Jay Sosenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sims E, Cuthbertson D, Jacobsen L, Ismail H, Nathan B, Herold K, et al.
J Clin Endocrinol Metab
. 2024 Jan;
109(8):2116-2123.
PMID: 38267821
Context: Metabolic measures are frequently used to predict type 1 diabetes (T1D) and to understand effects of disease-modifying therapies. Objective: Compare metabolic endpoints for their ability to detect preventive treatment...
2.
Ismail H, Cuthbertson D, Gitelman S, Skyler J, Steck A, Rodriguez H, et al.
Diabetes Care
. 2022 Aug;
45(10):2264-2270.
PMID: 35998266
Objective: To define the relationship between glucose and C-peptide during the progression to type 1 diabetes (T1D). Research Design And Methods: We longitudinally studied glucose and C-peptide response curves (GCRCs),...
3.
Baidal D, Warnock M, Xu P, Geyer S, Marks J, Moran A, et al.
J Clin Endocrinol Metab
. 2022 May;
107(8):e3273-e3280.
PMID: 35524749
Context: Decreased first-phase insulin response (FPIR) during intravenous glucose tolerance testing (IVGTT) is an early indicator of β-cell dysfunction and predictor of type 1 diabetes (T1D). Objective: Assess whether oral...
4.
Felton J, Cuthbertson D, Warnock M, Lohano K, Meah F, Wentworth J, et al.
Diabetologia
. 2021 Oct;
65(1):88-100.
PMID: 34642772
Aims/hypothesis: Methods to identify individuals at highest risk for type 1 diabetes are essential for the successful implementation of disease-modifying interventions. Simple metabolic measures are needed to help stratify autoantibody-positive...
5.
Snowhite I, Pastori R, Sosenko J, Cayetano S, Pugliese A
Diabetes
. 2020 Dec;
70(2):638-651.
PMID: 33277338
Type 1 diabetes is an autoimmune disease resulting in severely impaired insulin secretion. We investigated whether circulating microRNAs (miRNAs) are associated with residual insulin secretion at diagnosis and predict the...
6.
Ismail H, Becker D, Libman I, Herold K, Redondo M, Atkinson M, et al.
Diabetes Obes Metab
. 2020 Feb;
22(6):997-1000.
PMID: 32003110
We examined whether the timing of the C-peptide response during an oral glucose tolerance test (OGTT) in relatives of patients with type 1 diabetes (T1D) is predictive of disease onset....
7.
Redondo M, Sosenko J, Libman I, McVean J, Tosur M, Atkinson M, et al.
J Clin Endocrinol Metab
. 2019 Dec;
105(5).
PMID: 31867614
Context: Multiple islet autoantibody positivity usually precedes clinical (stage 3) type 1 diabetes (T1D). Objective: To test the hypothesis that individuals who develop stage 3 T1D with only a single...
8.
Redondo M, Evans-Molina C, Steck A, Atkinson M, Sosenko J
Diabetes Care
. 2019 Jun;
42(8):1357-1364.
PMID: 31167894
Current efforts to prevent progression from islet autoimmunity to type 1 diabetes largely focus on immunomodulatory approaches. However, emerging data suggest that the development of diabetes in islet autoantibody-positive individuals...
9.
Jacobsen L, Larsson H, Tamura R, Vehik K, Clasen J, Sosenko J, et al.
Pediatr Diabetes
. 2019 Jan;
20(3):263-270.
PMID: 30628751
Objective: The capacity to precisely predict progression to type 1 diabetes (T1D) in young children over a short time span is an unmet need. We sought to develop a risk...
10.
Redondo M, Steck A, Sosenko J, Anderson M, Antinozzi P, Michels A, et al.
Diabetes Care
. 2018 Oct;
41(12):2480-2486.
PMID: 30275285
Objective: The type 2 diabetes-associated alleles at the locus mark a type 1 diabetes phenotype characterized by single islet autoantibody positivity as well as lower glucose and higher C-peptide measures....